One major reason why it has been difficult to develop an effective HIV vaccine is that the virus mutates very rapidly, ...

XEC is also an offshoot of omicron, the widely spread variant that formed in 2021. According to experts, it has some of omicron’s features, too — like less severe symptoms and easy transmissibility.

Health data show that COVID-19 still surpasses all other infectious respiratory illnesses as a cause of severe illness, ...

Researchers have shown that they can generate a strong immune response against HIV with two doses of a vaccine given one week apart.

Yet many people don’t seem to recognize this—and this is a missed opportunity. Helping people to rethink side effects as ...

The F.D.A. authorized AstraZeneca’s treatment to be given outside a health care setting, although it will still need a ...

Global AI-based Fever Detection Camera Market is valued at approximately USD 1.61 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 8.2% over the forecast period ...

COVID-19 levels in the United States are high and rising, flu season is approaching quickly, and RSV cases are already ...

Milestone marks a significant step toward producing mRNA vaccines in Canada by 2025 CAMBRIDGE, MA / ACCESSWIRE / September 9, 2024 / Moderna, Inc. (Nasdaq:MRNA) today announced that its manufacturing ...

Vaccination against respiratory syncytial virus for adults over 60 is likely cost-effective by preventing illness, hospitalizations, lost quality of life and deaths, according to new research.

The FDA says the latest vaccine formulae "closely targets currently circulating variants" to give better protection against serious COVID-19 impacts.

The Vaccine Innovation Center at Korea University College of Medicine (VIC-K, Director Heejin Cheong) has entered into a full-scale collaboration with global pharmaceutical company Moderna to ...